New pharmacokinetic modeling data presented by teva simulates clinical profiles of schizophrenia patients switching to uzedy® (risperidone) extended-release injectable suspension at sirs 2024

Tel aviv, israel & parsippany, n.j.--(business wire)--teva pharmaceuticals, a u.s. affiliate of teva pharmaceutical industries ltd. (nyse and tase: teva), today announced the presentation of eight studies from its lai schizophrenia research program, including data evaluating uzedy, an extended-release injectable suspension of risperidone for subcutaneous use every one or two months for the treatment of schizophrenia in adults. the data were presented at the 2024 congress of the schizophrenia in.
TEVA Ratings Summary
TEVA Quant Ranking